SCHEMBL5554589

SCHEMBL5554589

Cc1c(CC(=O)O)c2c(F)c(O)c(F)cc2n1C(=O)c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 8/20 0.53
AKR1C2 P52895 8/20 0.53
ABCB1 P08183 3/20 0.51
PTGS1 P23219 3/20 0.51
PTGS2 P35354 3/20 0.51
AKR1C4 P17516 2/20 0.51
AKR1C1 Q04828 2/20 0.51
LMNA P02545 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP2D6 P10635 2/20 0.51
CYP2C9 P11712 2/20 0.51
HIF1A Q16665 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
PPARG P37231 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
PTGES O14684 1/20 0.51
ABCC3 O15438 1/20 0.51
ABCC4 O15439 1/20 0.51
ABCB11 O95342 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6426695 0.91 PTGS2 (0.52) AKR1C3AKR1C2ABCB1PTGS1PTGS2
SCHEMBL5553808 0.90 AKR1C3 (0.55) AKR1C3AKR1C2PTGS1PTGS2HIF1A
SCHEMBL5553844 0.90 PTGS2 (0.49) AKR1C3AKR1C2ABCB1PTGS1PTGS2
SCHEMBL6427040 0.89 PTGS2 (0.53) AKR1C3AKR1C2PTGS1PTGS2NPSR1
SCHEMBL5558356 0.88 PTGS2 (0.46) AKR1C3AKR1C2PTGS1PTGS2
SCHEMBL5559748 0.88 PTGS2 (0.45) AKR1C3AKR1C2PTGS1PTGS2NPSR1
SCHEMBL5554131 0.88 PTGS2 (0.46) AKR1C3AKR1C2PTGS2
SCHEMBL5554002 0.88 PTGS2 (0.47) AKR1C3AKR1C2PTGS1PTGS2MAPT
SCHEMBL6424711 0.88 PTGS2 (0.47) AKR1C3AKR1C2PTGS2PPARG
SCHEMBL5558197 0.87 PTGS2 (0.48) AKR1C3AKR1C2PTGS2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293542-A1 Selective Cox-2 Inhibitors IRONWOOD PHARMACEUTICALS, INC. 2007-12-20 US disclosed
US-20070293542-A1 Selective Cox-2 Inhibitors IRONWOOD PHARMACEUTICALS, INC. 2007-12-20 US disclosed
EP-1643961-A4 COX-2 AND FAAH INHIBITORS MICROBIA INC (US) 2007-09-12 EP disclosed
EP-1643961-A2 COX-2 AND FAAH INHIBITORS Microbia, Inc. (US) 2006-04-12 EP disclosed
US-20050032747-A1 COX-2 and FAAH inhibitors POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2005-02-10 US disclosed
WO-2005002525-A2 COX-2 AND FAAH INHIBITORS MICROBIA, INC. (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293542-A1 Selective Cox-2 Inhibitors PTGS2, FAAH2, PTGES2 AKR1C3 1000/4885AKR1C2 862/4885ABCB1 1286/4885
US-20050032747-A1 COX-2 and FAAH inhibitors FAAH2, FAAH, PTGS2 AKR1C3 585/4885AKR1C2 342/4885ABCB1 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.